MetaboLights

application/xml

ftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/m_MTBLS13737_LC-MS_positive_hilic_metabolite_profiling_v2_maf.tsvftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/s_MTBLS13737.txtftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/a_MTBLS13737_LC-MS_positive_hilic_metabolite_profiling.txtftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/i_Investigation.txtftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/NC-2.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/PD-6.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/NC-5.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/NC-13.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/NC-10.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/PD-3.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/PD-10.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/NC-4.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/PD-8.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/NC-7.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/PD-13.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/PD-2.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/NC-1.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/PD-5.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/PD-14.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/PD-11.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/NC-11.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/PD-7.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/NC-14.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/PD-4.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/NC-3.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/NC-9.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/NC-6.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/PD-12.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/NC-12.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/PD-1.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/NC-8.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/PD-9.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/NC-15.mzML.zipftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737/FILES/PD-15.mzML.zipprimaryOK200ftp://ftp.ebi.ac.uk/pub/databases/metabolights/studies/public/MTBLS13737The Multiquant software was used to extract chromatographic peak area and retention time. Use the standards correct retention time,to identify the metabolites.MetaboLightsPublicLiquid Chromatography MS - positive - hilicAnalyses were performed using an UHPLC (1290 Infinity LC, Agilent Technologies) coupled to a QTRAP MS (6500+, AB Sciex) in Shanghai Applied Protein Technology Co., Ltd. The analytes were separated on HILIC (Waters UPLC BEH Amide column, 2.1 mm × 100 mm, 1.7µm). For HILIC separation, the column temperature was set at 35 ℃; and the injection volume was 2 μL. Mobile phase A: 90% H2O + 2 mM ammonium formate + 10% acetonitrile , mobile phase B: 0.4% formic acid in acetonitrile. A gradient (85% B at 0-1 min, 80% B at 3-4min, 70% B at 6 min, 50% B at 10-15.5 min, 85% B at 15.6 -23 min ) was then initiated at a flow rate of 300 μL/min. A polled quality control (QC) samples were set in the sample queueto evaluate the stability and repeatability of the system. NLRP3 Senses L-Arginine to Inhibit Inflammasome Activation and Alleviate Parkinson’s disease Pathology.Feng LiuShanDong Universitybloodmass spectrometry assayThe samples were thawed at 4℃ and 100μL of each sample was mixed with 400μL of cold methanol/acetonitrile solution (1:1, v/v) containing isotope internal standards, adequately vortex, then ultrasounded for 5min at low temperature, followed by incubation at -20℃ for 1h. The mixture was centrifuged for 20min (14000rcf, 4℃). The supernatant was dried in a vacuum centrifuge, the samples were re-dissolved in 150μL acetonitrile/water (1:1, v/v) and adequately vortexed, and then centrifuged (14000rcf, 4℃, 15min). The supernatants were collected for LC-MS/MS analysis.Homo sapienshttps://www.ebi.ac.uk/metabolights/MTBLS13737Liu Feng. Shandong University. liufeng2019@sdu.edu.cn.Zhuang Wanxin. zwx145763@163.com.Gao Chengjiang. Shandong University. cgao@sdu.edu.cn.The processed data were analyzed by R package (ropls), where it was subjected to multivariate data analysis, including Pareto-scaled principal component analysis (PCA) and orthogonal partial least-squares discriminant analysis (OPLS-DA). The 7-fold cross-validation and response permutation testing were used to evaluate the robustness of the model. The variable importance in the projection (VIP) value of each variable in the OPLS-DA model was calculated to indicate its contribution to the classification. Student’s t test was applied to determine the significance of differences between two groups of independent samples. p value < 0.05 were used to screen significant changed metabolites. Pearson’s correlation analysis was performed to determine the correlation between two variables.Commercial databases including was used for pathway enrichment analysis.Groupliufeng2019@sdu.edu.cnHuman whole-blood samples (2 mL) were drawn into EDTA-coated tubes after an overnight fast. Within 30 min of collection, tubes were centrifuged at 3,000 × g, 4 °C for 10 min to obtain plasma.MetabolomicsMetabolismtargeted metabolitesAminoaciduriaMetabolismtargeted metabolitesAminoaciduriaMass spectrometry was performed on a QTRAP 6500+ system (AB Sciex) coupled to the UHPLC. The instrument was operated in polarity switching mode. For HILIC analysis (amino.mzML), the MS was primarily operated in positive ion mode with selective MRM transitions for polar metabolites. Common ESI source parameters: source temperature 580°C, Ion Source Gas 1 (GS1) 45, Ion Source Gas 2 (GS2) 60, Curtain Gas (CUR) 35, ion spray voltage +4500 V (positive mode) and -4500 V (negative mode). Multiple reaction monitoring (MRM) was used for quantitative data acquisition. Glutamic acidTaurineN-alpha-acetyllysineCysteineNorleucineSerineProlineLeucineGlycineHistidineArgininePyroglutamic acidKynurenineAspartic acidbeta-Alaninealpha-aminobutyric acidIsoleucineCreatinineTyrosineAlanineThreoninePhenylalanineMethionineTryptophanCitrullineValineCholineSarcosineNorvalineAsparagineArgininosuccinic acidOrnithineGlutaminefalseNLRP3 Senses L-Arginine to Inhibit Inflammasome Activation and Alleviate Parkinson’s disease PathologyWe screened a series of metabolites and found that L-Arg strongly inhibits NLRP3 inflammasome assembly in vitro. Mechanistically, L-Arg directly binds the D31 site of NLRP3, blocking NLRP3-ASC interaction and subsequent inflammasome assembly. This discovery establishes NLRP3 as a direct sensor for L-Arg. Additionally, L-Arg supplementation inhibits NLRP3 inflammasome activation in macrophages, while deprivation promotes it. Treatment with L-Arg in mice alleviates the MSU-induced arthritis and Alum-induced peritonitis. These findings reveal a new link between L-Arg metabolic homeostasis and inflammasome activation under physiological conditions. Moreover, we show decreased serum L-Arg levels in PD patients. In PD mouse models, L-Arg supplementation alleviates disease symptoms by modulating the NLRP3 inflammasome, whereas an L-Arg-deficient diet conversely exacerbates them. Our study uncovers a novel function of NLRP3 as a sensor for amino acid metabolism and demonstrates the new mechanism by which L-Arg regulates NLRP3 inflammasome activation, thereby offering a novel potential therapeutic strategy for inflammasome-related diseases.2026-09-022026-01-21MTBLS13737HMDB0000517HMDB0000214HMDB0000904HMDB0000052HMDB0000191HMDB0000168HMDB0000159HMDB0000929HMDB0000452HMDB0000684HMDB0000687HMDB0001645HMDB0000172HMDB0000696HMDB0013716HMDB0000883HMDB0000158HMDB0000251HMDB0000267HMDB0000162HMDB0000271HMDB0000056HMDB0000161HMDB0000167HMDB0000123HMDB0000641HMDB0000177HMDB0000187HMDB0000446HMDB0000148HMDB0000097HMDB0000562HMDB0000574